Caribou Biosciences, Inc.

NASDAQ:CRBU

Biotechnology

Healthcare
$0.49 -2.74%

-$0.05 today

Market cap
$52.47M
Beta
2.33
P/E (TTM)
-1.1
EPS (TTM)
-$1.39
52W Low $1.20High $3.54

Volume 1.01M

Average 1.83M

CRBU Revenue

Total income from selling goods and services before any costs are deducted; the top line of the income statement.

Caribou Biosciences, Inc.NASDAQ: CRBU

Revenue · Q1 FY2026 · quarter ended Mar 2026

Revenue grows, but more slowly than its trailing trend

Q1 FY2026 revenue of $2.4M rose 1.9% year over year, behind the +13.0% change in trailing-twelve-month revenue. Sequentially, it fell 39.2% from the prior quarter. Over 3 fiscal years it compounded at -7.0% a year.

Context

  • Revenue increased in 2 of the last 3 fiscal years.

What to watch

Whether revenue reaches the consensus estimate from 4 analysts of $8.72M (-21.9%) for the fiscal year ending Dec 2026, a slowdown from the +11.7% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
$2.4M-39.2% QoQ
Last fiscal yearDec 2025
$11.16M+11.7% YoY
LTMMar 2026
$11.2M+13.0% YoY
Revenue past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+1.9%-14.5%-16.4 pp
1 year+11.7%-21.9%-33.5 pp
3-year CAGR-7.0%-10.8%-3.8 pp
5-year CAGR+53.5%—
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Revenue history

USD · from the income statement

Latest · FY2025
11.16M USD
Year-over-year change
+11.7%
4-year CAGR
+3.8%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Revenue vs competitors

How CRBU compares with its peers on the latest reported figures

  • Peers report in different currencies, so revenue is compared through growth and rates rather than absolute size.
  • Its year-over-year change of +13.0% is the 4th highest of 7, against a peer median of +13.7%.
  • Over three fiscal years its annual growth of -7.0% compares with a peer median of +9.2%.
CRBU Competitors
Revenue for CRBU and competitors
Company Period LTM YoY 3-year CAGR
ENTAEnanta Pharmaceuticals, Inc.LTM Mar 2026$69.21M USD+7.4%-8.8%
OBIOOrchestra BioMed Holdings, Inc.LTM Mar 2026$32.72M USD+1033.9%+111.6%
FHTXFoghorn Therapeutics Inc.LTM Mar 2026$28.22M USD+20.1%+17.1%
PRLDPrelude Therapeutics IncorporatedLTM Mar 2026$16.72M USD+138.9%—
PYXSPyxis Oncology, Inc.LTM Mar 2026$13.86M USD——
CRBUCaribou Biosciences, Inc.LTM Mar 2026$11.2M USD+13.0%-7.0%
IVAInventiva S.A.FY2025€4.48M EUR-51.3%-28.3%
HUMAHumacyte, Inc.LTM Mar 2026$2.02M USD-74.0%+9.2%
TNYATenaya Therapeutics, Inc.LTM Mar 2026$225K USD——
ALLOAllogene Therapeutics, Inc.LTM Mar 2026$0 USD——
AARDAardvark Therapeutics, Inc. Common StockLTM Mar 2026$0 USD——
Peer median (excluding CRBU) —+13.7%+9.2%

Competitors are the stored peer set for CRBU. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue9.6M13.85M34.48M9.99M11.16M
Cost of Revenue984K3.64M3.53M3.93M3.65M
Gross Profit8.61M10.21M30.95M6.07M7.51M
Gross Margin89.7%73.7%89.8%60.7%67.3%
Research & Development52.26M82.23M112.08M130.15M109.44M
Selling, General & Admin23.34M38.02M38.46M46.46M37.91M
Operating Expenses75.59M116.61M147.01M172.68M143.71M
Depreciation & Amortization984K3.64M3.53M3.93M3.65M
EBITDA(65.61M)(95.71M)(98.35M)(145.19M)(145.03M)
EBITDA Margin-683.6%-691.0%-285.3%-1452.7%-1299.7%
Operating Income(66.98M)(106.4M)(116.06M)(166.62M)(136.19M)
Operating Margin-697.8%-768.2%-336.6%-1667.2%-1220.5%
Interest Income148K4.6M10.7M08M
Interest Expense8K0000
Other Income / Expenses377K7.05M14.18M17.5M(12.48M)
Income Before Tax(66.6M)(99.35M)(101.88M)(149.11M)(148.68M)
Pre-Tax Margin-693.9%-717.3%-295.5%-1492.0%-1332.3%
Income Tax Expense321K70K193K(9K)(550K)
Net Income(66.92M)(99.42M)(102.07M)(149.11M)(148.13M)
Net Margin-697.3%-717.8%-296.1%-1491.9%-1327.4%
EPS (Basic)(1.11)(1.64)(1.38)(1.65)(1.59)
EPS (Diluted)(1.11)(1.64)(1.38)(1.65)(1.59)
Weighted Avg Shares60.26M60.8M73.81M90.32M93.39M
Weighted Avg Shares (Diluted)60.26M60.8M73.81M90.32M93.39M

Caribou Biosciences, Inc.

NASDAQ:CRBU

Intrinsic Alpha fair value

Locked

Current Price

$0.49

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.